Type 1 Diabetes Across a Woman’s Life:
The Cycle, Contraception, Pregnancy and Menopause
The hormones move, and so does the glucose. Read the plain version with Jude, earn your way into the evidence with Grace, then the full picture with John. Stop wherever you have enough.
How we teach: three rules, borrowed from Taleb
You earn each level by showing you understand it, not by scrolling past it. We only teach what we would use on ourselves and the people we love.
Understanding beats memory and luck, so the checks reshuffle every time you retry. A pass means you got it, not that you guessed it. And we teach you to tell a trend (signal) from one reading (noise).
We give you the scaffolding and get out of your way. Roam where your curiosity leads, go as deep as you want, and ask Grace anything. We will not teach a bird how to fly.
Want to read this against your own cycle, in your units? Ask Grace, then take it to your care team.
One page, three depths
This guide compounds: each layer rests on the one beneath it. Read Jude’s plain version, then pass a short understanding check to open Grace, then another to open John. You can roam freely within a layer; you cannot skip ahead a layer, because the next one would not make sense and you would be standing on a gap.
The whole thing, in plain words
The same food, the same dose, the same walk, and yet the glucose runs higher this week than last. You did nothing wrong. Hormones change how your body answers insulin, and those hormones move on a schedule: across the month, across a pregnancy, and across the years either side of menopause. The glucose is reporting a real change, honestly. It is a body question, not a discipline question.
The biggest pattern is the monthly one. In the second half of the cycle, the week or so before a period, the hormone progesterone rises and the body often needs more insulin for the same food. When the period starts, the need usually drops back. Not everyone feels this; among women with type 1, roughly six or seven in ten notice a clear shift in the week before a period, and how big it is varies a great deal from person to person.1 Your own pattern matters more than the average.
The same idea runs through the bigger moments. Starting or changing contraception can nudge your insulin need in either direction for a few weeks. Planning a pregnancy is the one time the aim shifts to a tighter range, planned in advance with a specialist team, because it protects both you and the baby. And the years around menopause can make glucose wobble before things settle. Each of these is a moment to ask your team for a settings review, not a moment to push harder alone.
A common monthly shape, not a rule. The shaded band is wide on purpose: about six or seven in ten women notice this, and the size of the shift differs from person to person. Your own three months of data tell you your shape.
Does this match the life of the person living it? If your numbers seem to misbehave on a schedule you did not choose, you are not failing. You are reading a real rhythm. Name the pattern, and bring it to the people who can adjust with you.The Pemberton lens, lived recognisability, one of the four GNL appraisal lenses.
What the studies actually show
The cycle, measured phase by phase
The clearest single dataset is Tatulashvili 2022, which followed 64 premenopausal women with type 1 using CGM across the cycle.2 Time in range, the 3.9 to 10.0 mmol/L (70 to 180 mg/dL) band, moved by about 11 percentage points between the easiest and hardest phase. Notably, the lowest time in range was the follicular phase, not the luteal phase that usually gets the blame; and the highest hypoglycaemia and variability sat around ovulation.
| Cycle phase | Roughly which days | Time in range (median) | Time below range | Variability (CV) |
|---|---|---|---|---|
| Menstrual | 1 to 5 | 74.8% (highest) | lower | moderate |
| Follicular | 6 to 13 | 63.3% (lowest) | lower | 25.8% (lowest) |
| Ovulatory | around 14 | 74.1% | 1.0% (highest) | 29.5% (highest) |
| Luteal | 15 to 28 | 66.8% | moderate | moderate |
B Tatulashvili 2022, the largest single phase-by-phase CGM dataset in T1D (n equal to 64).2 Population medians, not a forecast for any one person. The wider systematic review (Gamarra 2023) confirms the direction: cycle phase shifts glucose measurably, with large individual variation.1 A separate strand of work finds the late luteal week, the days before a period, often needs more insulin for the same food, driven by rising progesterone.3
Does an automated system simply handle it?
Partly, not fully. On Tandem Control-IQ, time in range still dropped in the luteal phase even though the algorithm raised insulin on its own (Levy 2022).4 The same partial-compensation pattern shows on MiniMed 780G (Monroy 2025) and in hypoglycaemia-prone users on advanced closed loop (Mesa 2024).5 The headline is consistent: automated insulin delivery reduces the cycle effect but does not abolish it; none of the current systems takes cycle phase as a direct input. Phase-aware tracking still earns its place.
Contraception, pregnancy planning, menopause
Contraception. The Cochrane review (Visser 2013) found most methods leave glucose broadly stable; only high-dose combined pills, and one specific older combination, mildly impaired glucose handling, and the hormonal coil showed no meaningful difference from a copper coil.6 The method choice is a personal one made with your GP or sexual-health team; the diabetes layer is simply to watch CGM for two or three cycles after a change and ask for a settings review if your pattern shifts.
Pregnancy planning. This is the one place targets tighten, in advance and with a specialist team. UK guidance aims for a pre-conception HbA1c below 48 mmol/mol (6.5%) where it is safely reachable, with 5 mg folic acid daily.7 In pregnancy itself the range narrows to 3.5 to 7.8 mmol/L (63 to 140 mg/dL) with a time-in-range aim of at least 70%.7 8 CGM is standard of care, and an automated system (CamAPS FX in the AiDAPT trial) improved time in range over standard therapy.8
Menopause. Here the evidence is thinnest. The most recent T1D-specific review (Courtney and Owens 2025) describes oestrogen withdrawal nudging insulin resistance up, sleep disrupted by hot flushes worsening overnight glucose, and HRT generally improving control by partly restoring sensitivity; all of it rests on small observational studies, with no menopause-specific automated-system trial yet.9
Notice how the strength of evidence falls as you move along the life course: a 64-woman CGM study for the cycle, a Cochrane review for contraception, two large trials for pregnancy, and a single narrative review for menopause. Same topic, very different floors of certainty. Always ask what the claim is standing on.The Goldacre lens, evidence-grade discipline, one of the four GNL appraisal lenses.
The mechanism, the numbers, the limits
Why the glucose moves
Two ovarian hormones pull in opposite directions. Oestrogen tends to improve insulin sensitivity; progesterone tends to reduce it. Across a natural cycle the follicular phase is oestrogen-led, the luteal phase is progesterone-dominant, and the late luteal week is where insulin need most often rises, sometimes by a useful margin for the same carbohydrate. Brown 2015 documented exactly this with blinded CGM across three cycles, finding nocturnal insulin sensitivity dropping from the early follicular phase into the luteal phase.3 The same lever explains the rest of the life course: contraception adds exogenous hormone, pregnancy ramps placental insulin resistance trimester by trimester, and menopause withdraws oestrogen.
The evidence, by certainty
| Life-course question | Best current anchor | What it supports | Grade |
|---|---|---|---|
| Cycle shifts glucose | Gamarra 2023 systematic review; Tatulashvili 2022 (n=64) | Real, measurable, roughly an 11-point TIR swing; direction reliable, magnitude individual | A B |
| AID does not abolish it | Levy 2022; Monroy 2025; Mesa 2024 | Algorithm partly compensates; phase effect persists | B |
| Contraception and glucose | Visser 2013 Cochrane | Most methods stable; high-dose combined pill a caution; small, old base | A |
| PCOS more common in T1D | Codner 2007; Teede 2023 guideline | Elevated prevalence; gynaecology-led work-up; OGTT screening | A |
| Pregnancy: CGM and AID help | CONCEPTT 2017; AiDAPT 2023 | Higher TIR, better neonatal outcomes; standard of care | A |
| Menopause changes need | Courtney 2025; Slopien 2018 EMAS | Resistance up on oestrogen withdrawal; HRT may help; no AID trial | D |
The menopause row is a single narrative review plus a largely type-2 European guide. There is no automated-system trial in perimenopause or menopause for type 1, and no modern formulation-specific contraception trial using CGM. These are honest gaps, not settled facts; treat any confident menopause-and-T1D claim with care.9
Reading your own pattern, the right way round
The population table is a frame, not your answer. The reliable method is to overlay three or more complete cycles of CGM with the cycle logged, look for the phase that repeatedly costs you time in range, and bring that specific pattern to a settings review. Some teams use a temporary lever for the luteal week, a raised target on a 780G, the boost function on CamAPS FX, a short basal increase on injections; each is a care-team conversation, never a self-prescription. The same proactive-review habit serves every transition: a new contraceptive, pregnancy planning, the perimenopausal years.
The pre-conception aim is a band approached steadily with a specialist team, only as tight as it can be without hypos. It is a planned target, not a daily race; the cycle and pregnancy targets are different questions.
Build for the swing you cannot afford, not the average month. Around ovulation the lows run highest; in the late luteal week the highs creep up. Robustness means protecting hardest against the rare catastrophic low while smoothing the predictable drift, rather than chasing a flawless flat line.The Taleb lens, robustness to outliers, one of the four GNL appraisal lenses.
A model is only as honest as its weakest source. This life-course picture is strong at the cycle and pregnancy ends and weak at menopause; saying so plainly is the point. Name what would strengthen each row, a CGM contraception trial, a menopause AID study, and never present the strong rows and the thin rows as if they carried equal weight.The Hayes lens, technical and methodological rigour, one of the four GNL appraisal lenses.
The whole guide, summarised
Glucose never lies; it just keeps an honest record of a body whose hormones move. Read it kindly, find your pattern, and bring it to the people who can adjust with you.
This page is the taster. The full journey, three modules and their 30 questions, with your progress saved, lives in Learn with Grace. Glucose never lies; come and learn to read it across your whole life.
References
Evidence grades A (strongest) to D (narrative or working analysis).
- Gamarra M, Trimboli P. The menstrual cycle and its effects on glucose control and insulin sensitivity in women with type 1 diabetes: a systematic review. J Pers Med. 2023;13(3):532. A
- Tatulashvili S, et al. Ambulatory glucose profile across menstrual cycle phases in women with type 1 diabetes. J Clin Endocrinol Metab. 2022;107(10):dgac443. (n equal to 64; the largest single phase-by-phase CGM dataset.) B
- Brown SA, et al. Fluctuations of hyperglycaemia and insulin sensitivity linked to menstrual cycle phases. J Diabetes Sci Technol. 2015;9(6):1252-1258. B
- Levy CJ, et al. Glycaemic outcomes across the menstrual cycle on Tandem Control-IQ closed-loop: a pre-specified secondary analysis of the iDCL trial. Diabetes Technol Ther. 2022. B
- Monroy I, et al. MiniMed 780G use across the menstrual cycle (780MENS). Diabetes Technol Ther. 2025; and Mesa A, et al. Advanced hybrid closed-loop and late-luteal hypoglycaemia in hypoglycaemia-prone T1D. Diabetes Technol Ther. 2024. B
- Visser J, Snel M, Van Vliet HAAM. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database Syst Rev. 2013, Issue 3. Art. No.: CD003990. A
- NICE NG3, Diabetes in Pregnancy: management from preconception to the postnatal period. 2015, last updated December 2020. (Pre-conception HbA1c below 48 mmol/mol where safe; pregnancy range 3.5 to 7.8 mmol/L; 5 mg folic acid.) A
- Lee TTM, et al. (AiDAPT). Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med. 2023;389(17):1560-1571; and Feig DS, et al. (CONCEPTT). Lancet. 2017;390(10110):2347-2359. A
- Courtney A, Owens L. Current evidence and research gaps in menopause management in women with type 1 diabetes mellitus: a narrative review. Endocrine Connections. 2025;14:e250486; and Slopien R, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6-10. D
- Teede HJ, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469; and Codner E, et al. PCOS and ovarian morphology in women with type 1 diabetes. J Clin Endocrinol Metab. 2007. A
One page, three voices: Jude, Grace, John. Population-average, not personalised.